Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Schwartz GN, Kaufman PA, Giridhar KV, Marotti JD, Chamberlin MD, Arrick BA, Makari-Judson G, Goetz MP, Soucy SM, Kolling F, Demidenko E, Miller TW. Schwartz GN, et al. Clin Cancer Res. 2023 Aug 1;29(15):2767-2773. doi: 10.1158/1078-0432.CCR-23-0112. Clin Cancer Res. 2023. PMID: 37260292 Free PMC article.
Cognitive function in breast cancer patients prior to adjuvant treatment.
Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA. Ahles TA, et al. Among authors: schwartz gn. Breast Cancer Res Treat. 2008 Jul;110(1):143-52. doi: 10.1007/s10549-007-9686-5. Epub 2007 Aug 3. Breast Cancer Res Treat. 2008. PMID: 17674194 Free PMC article.
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW. Bean JR, et al. Among authors: schwartz gn. Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10. Breast Cancer Res Treat. 2015. PMID: 25491778 Free PMC article.
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ, Gorlov IP, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata AA, Dragnev KH, Fadul CE, Schwartz GN, Morgan CR, Holderness BM, Peterson JD, Tsongalis GJ, Miller TW, Chamberlin MD. Tafe LJ, et al. Among authors: schwartz gn. Oncologist. 2015 Sep;20(9):1011-8. doi: 10.1634/theoncologist.2015-0097. Epub 2015 Jul 23. Oncologist. 2015. PMID: 26205736 Free PMC article.
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD, Wells JD, Shee K, Bean JR, Marotti JD, Wells WA, Trask HW, Kolling FW, Bhatt A, Kaufman PA, Schwartz GN, Gemery JM, McNulty NJ, Tsapakos MJ, Barth RJ, Arrick BA, Gui J, Miller TW. Chamberlin MD, et al. Among authors: schwartz gn. Breast Cancer Res Treat. 2020 Aug;182(3):665-677. doi: 10.1007/s10549-020-05714-2. Epub 2020 Jun 19. Breast Cancer Res Treat. 2020. PMID: 32562118 Free PMC article.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR 3rd, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Kaufman PA, Ashley EJ, Perez-Olle R, Hong S, Rosales MK, Gradishar WJ; SOPHIA Study Group. Rugo HS, et al. Among authors: schwartz gn. J Clin Oncol. 2023 Jan 10;41(2):198-205. doi: 10.1200/JCO.21.02937. Epub 2022 Nov 4. J Clin Oncol. 2023. PMID: 36332179 Free PMC article. Clinical Trial.
72 results